retatrutide ada 2025 results 2026: Revolution Retatrutide shows substantial weight loss,

J.C.Wendl

Elderly patients over 75 may face heightened risk of dehydration, acute kidney injury, and pancreatitis with GLP-1 therapy, requiring individualized assessment and often lower starting doses

This article is for educational purposes only

For the newest retatrutide data in people with type 2 diabetes, severe obesity, and heart disease, read our July 2026 Retatrutide Phase 3 results guide

avoid vigorous shaking to prevent degradation

Use caution and monitor renal function when initiating or increasing doses of semaglutide in patients with renal impairment or any patients who report severe gastrointestinal reactions during use